CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 Year

Similar documents
Faculty/Presenter Disclosure

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Off-Pump or On-Pump Coronary-Artery Bypass Grafting at 30 Days

Heart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People

TICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL

The MAIN-COMPARE Study

Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

On-Pump vs. Off-Pump CABG: The Controversy Continues. Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

Supplement materials:

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

The TNT Trial Is It Time to Shift Our Goals in Clinical

Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB

Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière

Evolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC)

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

Coronary Artery Bypass Grafting in Diabetics: All Arterial or Hybrid?

Unprotected LM intervention

1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES

Declaration of conflict of interest NONE

Cindy L. Grines MD FACC FSCAI

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION

The ACCELERATE Trial

Management of cardiovascular disease - coronary interventions -

TRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital

Abbott Vascular. PROTOCOL EXCEL Clinical Trial

Patient characteristics Intervention Comparison Length of followup

Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial)

Experiences with interim trial monitoring, particularly with early stopped trials

HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD

Adults With Diagnosed Diabetes

Fractional Flow Reserve Guided PCI versus Medical Therapy in Stable Coronary Disease. FAME 2 Trial

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.

ICSS Safety Results NOT for PUBLICATION. June 2009 ICSS ICSS ICSS ICSS. International Carotid Stenting Study: Main Inclusion Criteria

Disclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

The MAIN-COMPARE Registry

Is there enough evidence for DAPT after endovascular intervention for PAOD?

Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG-SAFE)

The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Quality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease:

2. If prasugrel is found to be both more costly and more effective than clopidogrel, to assess its costeffectiveness

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

Apixaban Versus ASA To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute Hamilton, Ontario, Canada

Timing of angiography for high- risk ACS

RIVAL study: RadIal Vs. femoral access for coronary intervention in patients with acute coronary syndromes study. Sanjit Jolly MD, MSc FRCPC

SUPPLEMENTAL MATERIAL

PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome

Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France

The Second Best Arterial Graft:

Expert Meeting on Large Simple Trials (LST s)

Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombosis

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

COURAGE to Leave Diseased Arteries Alone

INDIVIDUALIZED MEDICINE

A Summary of Childhood Cancer Statistics in Australia,

Ischemic Heart Disease Interventional Treatment

PCI vs. CABG From BARI to Syntax, Is The Game Over?

Long-term safety, tolerability and efficacy of alirocumab in high cardiovascular risk patients: ODYSSEY LONG TERM

Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011

Global Variations in the 1-year Rates of Death and Stroke in Patients Presenting to the Emergency Department with Atrial Fibrillation

Count Down to COMBAT

Heart Outcomes Prevention Evaluation (HOPE) Study

Disclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim

Main Results Insulin Resistance Intervention after Stroke (IRIS) Trial

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

Supplementary webappendix

FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin

7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET)

An international, double-blind, phase III randomized trial. Main Results

The top 5 trials in the last year: Ischemic Heart Disease

Clinical Outcome in Patients with Aortic Stenosis

Preoperative Anemia versus Blood Transfusion: Which is the Culprit for Worse Outcomes in Cardiac Surgery?

CVD risk assessment using risk scores in primary and secondary prevention

Race Original cohort Clean cohort HR 95%CI P HR 95%CI P. <8.5 White Black

Ischemic Heart Disease Interventional Treatment

FFR in Multivessel Disease

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome

Emergency surgery in acute coronary syndrome

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Ticagrelor vs Aspirin in Patients undergoing Coronary- Artery Bypass Grafting

CHOLESTEROL-LOWERING THERAPHY

JAMA. 2011;305(24): Nora A. Kalagi, MSc

To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.

Transcription:

CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study Results at 1 Year André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures: CORONARY was funded by a grant from the Canadian Institutes of Health Research (CIHR).

Background Benefits and risks of performing CABG surgery on beating heart (off pump) not clearly established. Meta-analyses of 59 trials involving 8961 pts No differences in major CV outcomes except strokes ROOBY (1 Year) Primary Outcome: Off-pump is worse (p=0.04) CV Deaths: Off-pump is worse (p=0.03) 2

CORONARY Trial Organization 79 centers in 19 countries 4,752 patients recruited between (November 2006 October 2011) Designed, coordinated, managed and data analysed and reported by the Population Health Research Institute, Hamilton Health Sciences and McMaster University in Hamilton, Canada The data was monitored by independent DSMB Funded by Canadian Institutes of Health Research 3

Inclusion/Exclusion Criteria Inclusion Criteria Isolated CABG with median sternotomy One of the following: 1. Peripheral vascular disease 2. Cerebrovascular disease 3. Renal Insufficiency 4. Age 70 years 5. Age 60-69 with at least one risk factor (diabetes, urgent revascularization, smoker, LVEF 35%) 6. Age 55-59 with at least two of the above risk factors Exclusions Additional cardiac procedure planned Contraindications to off-pump or on-pump CABG Emergency or re-do CABG 5

Qualifications of Surgeons Surgical expertise-based randomization > 2 years of experience as staff cardiac surgeon and > 100 cases of one or both techniques Trainees were not allowed to be primary operators 6

Primary Outcomes 1 st Co-Primary Outcome Composite of total mortality, stroke, non fatal myocardial infarction, new renal failure at 30 days post randomization results presented ACC 2012 results at 1 year 2 nd Co-Primary Outcome Composite of above outcomes plus repeat coronary revascularization over 5 yrs of follow-up (expected 2016) 7

Baseline Characteristics OFF-PUMP (n = 2375) ON-PUMP (n = 2377) Mean Age (years) 67.6 67.5 Males (%) 80.0 81.7 Prior MI 33.8 35.2 Previous Stroke 6.7 7.8 Peripheral Arterial Disease 8.0 8.2 Congestive Heart Failure 5.9 6.6 Urgent Surgery 39.5 38.1 Euroscore 0 2 3 5 > 5 28.6 51.7 18.1 27.8 54.2 16.8 10

Baseline Disease Pre-op Angiogram OFF-PUMP (n = 2375) % ON-PUMP (n = 2377) % Left Main 22.1 20.9 Triple Vessel 56.1 60.4 Double Vessel 18.7 16.4 Single Vessel 3.0 2.1 11

1 st Co-Primary Outcome (1 Year) Off Pump % On Pump % Hazard Ratio 95% CI p value Primary Outcome Death, Stroke, MI, Renal Failure Components 12.1 13.3 0.91 0.77-1.07 0.24 Death 5.1 5.0 1.03 0.80-1.32 Stroke 1.5 1.7 0.90 0.57-1.41 Non Fatal MI 6.8 7.5 0.90 0.73-1.12 New Renal Failure 1.3 1.3 0.97 0.59-1.60 14

Cumulative Event Rate 0.0 0.05 0.10 0.15 0.20 Death/MI/Stroke/New Renal Failure at 1 Year On Pump CABG Off Pump CABG HR 0.91 95% CI 0.77-1.07 p value 0.24 0 3 6 9 12 15

Other Outcomes at 1 year Off Pump % On Pump % Hazard Ratio 95% CI p value Cardiovascular Mortality 4.2 4.0 1.03 0.78-1.37 0.83 Angina 1.0 0.9 1.05 0.58-1.88 0.87 PCI 1.1 0.8 1.43 0.79-2.57 0.23 Re-do CABG 0.3 0.04 7.00 0.86-57.0 0.07 PCI/Re-do CABG 1.4 0.8 1.66 0.95-2.89 0.07 Primary Outcome per Protocol 11.5 13.2 0.86 0.73-1.02 0.08 16

Primary Outcome between 31 days and 1 Year Off Pump % On Pump % Hazard Ratio 95% CI p value Primary Outcome Death/MI/Stroke/Renal Failure 2.6 3.2 0.79 0.55-1.13 0.19 Components Death 2.1 2.3 0.87 0.58-1.31 Stroke 0.5 0.6 0.83 0.36-1.92 Non Fatal MI 0.2 0.4 0.50 0.15-1.65 New Renal Failure 0.1 0.2 0.50 0.09 2.71 17

Other Outcomes between 31 days and 1 Year Off Pump % On Pump % Hazard Ratio 95% CI p value Cardiovascular Mortality 1.5 1.5 1.06 0.65-1.73 0.82 Angina 0.8 0.7 1.13 0.56-2.26 0.74 PCI 0.7 0.6 1.15 0.55-2.41 0.72 Re-do CABG <0.1 0 0.99 PCI/Re-do CABG 0.7 0.6 1.22 0.59-2.54 0.59 18

Quality of Life 19

Neurocognitive Function 20

Subgroups (1) 21

Subgroups (2) 22

Conclusions At 1 Year there was no difference between Off pump CABG and On pump CABG: Primary Outcome Individual components of the Primary Outcome Revascularization procedures Quality of Life Neurocognitive functions 23

Implications In experienced hands, both procedures are reasonable options based on mid-term results 24

Steering Committees A. Lamy (Co-PI) P.J. Devereaux J. Murkin D.P. Taggart D. Prabhakaran R.J. Novick A.R. Akar S.E. Fremes E. Paolasso A. Avezum S. Hu L. Piegas R. Cartier F. Lanas Z. Straka S. Chocron P.J. Lopez S. Yusuf (co-pi) 25

Final Recruitment by Country 4752 patients from 79 sites in 19 countries Canada (830) USA (68) Netherlands (27) Sweden (56) United Kingdom (227) France (4) Italy (48) Czech Republic (298) Estonia (91) Turkey (132) Ukraine (11) China (781) India (1307) Colombia (57) Brazil (358) Chile (137) Uruguay (34) Argentina (257) Australia (29) 26

27